Magnolia Neurosciences

📍 New York, United States🗓 Founded 2018👥 1 employees💰 Last funded Aug 2018
Biotechnology Research🌐 magnolianeurosciences.com
Website LinkedIn
Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company was launched by a $31 million Series A investment by Accelerator Life Science Partners in 2018 and was co-founded by world-class researchers at The University of Texas MD Anderson Cancer Center. The company endeavors to make life-changing medicines for the benefit of patients and their families suffering from serious CNS diseases. The company’s offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science campus.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Magnolia Neurosciences?
Magnolia Neurosciences has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Magnolia Neurosciences last raise funding?
The most recent investment in Magnolia Neurosciences recorded on gritt.io was in August 2018.
When was Magnolia Neurosciences founded?
Magnolia Neurosciences was founded in 2018.
What industry is Magnolia Neurosciences in?
Magnolia Neurosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Magnolia Neurosciences based?
Magnolia Neurosciences is headquartered in New York, United States.